- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Interventions
- JCXH-105, Shingrix
- Biological
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Long Beach, California • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Herpes Zoster Subunit (HZ/su) Vaccine, Placebo
- Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Oklahoma City, Oklahoma
- Conditions
- Herpes Zoster
- Interventions
- Data collection
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 2,844 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Canton, Massachusetts
- Conditions
- Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Zoster Vaccine Recombinant, Adjuvanted
- Biological
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
- Interventions
- Herpes Zoster (HZ) Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
- Conditions
- Herpes Zoster
- Interventions
- mRNA-1468, Placebo, Shingrix
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Longmont, Colorado • Lakeland, Florida + 16 more
- Conditions
- Herpes Zoster
- Interventions
- GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 11
- States / cities
- Oakland, California • Aurora, Colorado • Colorado Springs, Colorado + 7 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
- Interventions
- Shingrix vaccine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Shingles
- Interventions
- Zoster Vaccine Live
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- Interventions
- Herpes Zoster vaccine (GSK 1437173A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 651 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
- Conditions
- Zoster, Zoster Varicella, Shingles, Chicken Pox
- Interventions
- Shingrix®
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Inflammatory Bowel Diseases, IBD
- Interventions
- Adjuvanted Recombinant Zoster Vaccine (RZV)
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 19 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis
- Interventions
- Varicella Zoster Vaccine, Placebo Injection
- Biological · Other
- Lead sponsor
- Kevin Winthrop
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 5
- States / cities
- Boise, Idaho • Eagan, Minnesota • Clovis, New Mexico + 2 more
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation, Herpes Zoster (HZ)
- Interventions
- Shingrix
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Rheumatoid Arthritis, Varicella Zoster
- Interventions
- Zostavax (varicella zoster virus) vaccine
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Zoster, Pneumococcal Infections
- Interventions
- Enhanced immunization delivery model, Immunization update
- Behavioral · Other
- Lead sponsor
- Auburn University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Auburn, Alabama • Claremont, California
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 829 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
- Conditions
- Herpes Zoster
- Interventions
- Zostavax™
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Shingles, Herpes Zoster Infection, Human
- Interventions
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 484 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
- Conditions
- Osteosarcoma, Neuroblastoma
- Interventions
- GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2034
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Herpes Zoster
- Interventions
- Herpes zoster vaccine GSK1437173A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 354 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- Herpes Zoster
- Interventions
- HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Elkridge, Maryland • Charlotte, North Carolina + 5 more